[go: up one dir, main page]

WO2011080505A3 - Method of growing phage for commercial use - Google Patents

Method of growing phage for commercial use Download PDF

Info

Publication number
WO2011080505A3
WO2011080505A3 PCT/GB2010/002341 GB2010002341W WO2011080505A3 WO 2011080505 A3 WO2011080505 A3 WO 2011080505A3 GB 2010002341 W GB2010002341 W GB 2010002341W WO 2011080505 A3 WO2011080505 A3 WO 2011080505A3
Authority
WO
WIPO (PCT)
Prior art keywords
phage
growing
modified
industrial
commercial use
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2010/002341
Other languages
French (fr)
Other versions
WO2011080505A2 (en
Inventor
John Bernard March
Jason Richard Clark
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BigDNA Ltd
Original Assignee
BigDNA Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BigDNA Ltd filed Critical BigDNA Ltd
Publication of WO2011080505A2 publication Critical patent/WO2011080505A2/en
Publication of WO2011080505A3 publication Critical patent/WO2011080505A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/08—Reducing the nucleic acid content
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10311—Siphoviridae
    • C12N2795/10351—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention relates to methods of obtaining bacteriophage ('phage'), such as lambda phage, for industrial uses, such as for use in commercial vaccine production. There is also provided a novel bacterium, such as Escherichia coli (E. coli) which has been modified for growing phage in a manner which improves the general and environmental safety of said phage. The invention also relates to the use of a modified bacterium for growing phage for industrial purposes. Finally, the invention also provides modified phage, which are designed for growth in industrial and/or environmental safety.
PCT/GB2010/002341 2009-12-28 2010-12-24 Method of growing phage for commercial use Ceased WO2011080505A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29036209P 2009-12-28 2009-12-28
US61/290,362 2009-12-28

Publications (2)

Publication Number Publication Date
WO2011080505A2 WO2011080505A2 (en) 2011-07-07
WO2011080505A3 true WO2011080505A3 (en) 2011-08-25

Family

ID=43638606

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2010/002341 Ceased WO2011080505A2 (en) 2009-12-28 2010-12-24 Method of growing phage for commercial use

Country Status (1)

Country Link
WO (1) WO2011080505A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3882259A1 (en) 2015-05-13 2021-09-22 Synlogic Operating Company, Inc. Bacteria engineered to reduce hyperphenylalaninemia
CN111655841A (en) * 2017-06-21 2020-09-11 同生运营公司 bacteria used to treat disorders
CN109251899B (en) * 2018-09-30 2021-08-03 南京医科大学 Drug-resistant Escherichia coli phage and its application
AU2021240078A1 (en) 2020-03-20 2022-09-01 Synlogic Operating Company, Inc. Microorganisms engineered to reduce hyperphenylalaninemia
CN111607602A (en) * 2020-06-11 2020-09-01 华东理工大学 A method for reliable and stable production of polyols

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003076583A2 (en) * 2002-03-06 2003-09-18 Musc Foundation For Research Development Genetically engineered phage and the use of genetically engineered phage to deliver nucleic acid to bacteria
WO2007015704A2 (en) * 2004-10-29 2007-02-08 University Of Rochester Modified bacteriophage vectors and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2759882A1 (en) 1997-12-05 1999-06-17 Europaisches Laboratorium Fur Molekularbiologie Novel dna cloning method
WO1999051780A1 (en) 1998-04-08 1999-10-14 Robert Massey Targeting of specific cell types for removal by the immune system
CA2331384A1 (en) 1998-06-18 1999-12-23 Dnavec Research Inc. Nucleic acid transfer phage
US6355412B1 (en) 1999-07-09 2002-03-12 The European Molecular Biology Laboratory Methods and compositions for directed cloning and subcloning using homologous recombination
AT408949B (en) 2000-07-25 2002-04-25 Petrovic Dragan Dipl Ing VASCULAR ANCHORING DEVICE
GB0107319D0 (en) 2001-03-23 2001-05-16 Moredun Res Inst Bacteriophage-mediated immunisation
US6989265B2 (en) 2002-01-23 2006-01-24 Wisconsin Alumni Research Foundation Bacteria with reduced genome
EP2196215A1 (en) 2003-12-17 2010-06-16 The Catholic University Of America Method for making an immunogenic composition with Hoc fusion proteins and Soc fusion proteins
US8178339B2 (en) 2005-08-20 2012-05-15 Scarab Genomics Llc Reduced genome E. coli
US8754015B2 (en) 2006-11-21 2014-06-17 University Of Rochester Modified phage for displaying post-translationally modified proteins and uses thereof
US20110262472A1 (en) 2008-04-22 2011-10-27 Cytos Biotechnology Ag Vaccine compositions for the treatment of dengue fever and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003076583A2 (en) * 2002-03-06 2003-09-18 Musc Foundation For Research Development Genetically engineered phage and the use of genetically engineered phage to deliver nucleic acid to bacteria
WO2007015704A2 (en) * 2004-10-29 2007-02-08 University Of Rochester Modified bacteriophage vectors and uses thereof

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
BABA TOMOYA ET AL: "Construction of Escherichia coli K-12 in-frame, single-gene knockout mutants: the Keio collection.", MOLECULAR SYSTEMS BIOLOGY, vol. 2, 21 February 2006 (2006-02-21), XP002628975, ISSN: 1744-4292, DOI: 10.1038/msb4100050 *
E. COLI GENETIC RESOURCES AT YALE CGSC, THE COLI GENETIC STOCK CENTER: "Strain JW4279-1", XP002628984, Retrieved from the Internet <URL:http://cgsc.biology.yale.edu/Strain.php?ID=109347> [retrieved on 20110315] *
GUPTA A ET AL: "High-density Functional Display of Proteins on Bacteriophage Lambda", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 334, no. 2, 21 November 2003 (2003-11-21), pages 241 - 254, XP004470972, ISSN: 0022-2836, DOI: DOI:10.1016/J.JMB.2003.09.033 *
HANDA NAOFUMI ET AL: "ERRATUM: Type III restriction is alleviated by bacteriophage (RecE) homologous recombination function but enhanced by bacterial (RecBCD) function", JOURNAL OF BACTERIOLOGY, vol. 187, no. 21, February 2007 (2007-02-01), pages 1180, XP002628980, ISSN: 0021-9193 *
HANDA NAOFUMI ET AL: "Type III restriction is alleviated by bacteriophage (RecE) homologous recombination function but enhanced by bacterial (RecBCD) function", JOURNAL OF BACTERIOLOGY, vol. 187, no. 21, November 2005 (2005-11-01), pages 7362 - 7373, XP002628979, ISSN: 0021-9193 *
JEPSON C D ET AL: "Bacteriophage lambda is a highly stable DNA vaccine delivery vehicle", VACCINE, ELSEVIER LTD, GB, vol. 22, no. 19, 23 June 2004 (2004-06-23), pages 2413 - 2419, XP004515458, ISSN: 0264-410X, DOI: DOI:10.1016/J.VACCINE.2003.11.065 *
LANKES H A ET AL: "In vivo gene delivery and expression by bacteriophage lambda vectors", JOURNAL OF APPLIED MICROBIOLOGY, vol. 102, no. 5, May 2007 (2007-05-01), pages 1337 - 1349, XP002628981, ISSN: 1364-5072 *
MORADPOUR ZAHRA ET AL: "Genetically engineered phage harbouring the lethal catabolite gene activator protein gene with an inducer-independent promoter for biocontrol of Escherichia coli.", FEMS MICROBIOLOGY LETTERS JUL 2009 LNKD- PUBMED:19459966, vol. 296, no. 1, July 2009 (2009-07-01), pages 67 - 71, XP002628982, ISSN: 1574-6968 *
NOVAGEN: "Bacteriophage CE6", NOVAGEN TECHNICAL BULLETIN, no. 7, February 1994 (1994-02-01), pages 1 - 2, XP002628977, Retrieved from the Internet <URL:http://www.ebiotrade.com/buyf/productsf/Novagen/69390-000.pdf> [retrieved on 20110315] *
SAMBROOK JOSEPH ET AL: "Molecular cloning: A laboratory manual", vol. 1, 2001, COLD SPRING HARBOR LABORATORY PRESS, 10 SKYLINE DRIVE, PLAINVIEW, NY, 11803-2500, USA, ISBN: 0-87969-577-3, ISSN: null, article "Chapter 2: Bacteriophage Lambda and its vectors", pages: 2.28 - 2.29, XP002628976 *
SIMMON V F ET AL: "Degradation of bacteriophage lambda deoxyribonucleic acid after restriction by Escherichia coli K-12.", JOURNAL OF BACTERIOLOGY, vol. 112, no. 1, October 1972 (1972-10-01), pages 161 - 169, XP002628978, ISSN: 0021-9193 *

Also Published As

Publication number Publication date
WO2011080505A2 (en) 2011-07-07

Similar Documents

Publication Publication Date Title
CA2746228C (en) Modified rsv f proteins and methods of their use
MX2013007379A (en) Sandpaper mutants of bacillus and methods of their use to enhance plant growth, promote plant health and control diseases and pests.
WO2008153776A8 (en) Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using said compositions
WO2010138736A3 (en) A method to produce a highly concentrated immunoglobulin preparation for subcutaneous use
MXPA03002683A (en) ESCHERICHIA COLI CEPAS WHICH OVERPRODUCTS L-TREONIN AND PROCEDURES FOR PRODUCTION OF L-TREONIN BY FERMENTATION ..
WO2010085957A3 (en) Long shelf life milk and milk-related products, and a process and milk processing plant for their manufacture
WO2013016361A3 (en) Compositions and methods for controlling head blight disease
NZ593550A (en) ANTI-Siglec-15 ANTIBODY
WO2011003034A3 (en) Biological methods for preparing adipic acid
UA103176C2 (en) Plant with increased yield-related traits and method for its production
WO2013103268A3 (en) Microorganism able to produce l-amino acid, and method for producing l-amino acid by using same
WO2011080505A3 (en) Method of growing phage for commercial use
WO2008102720A1 (en) Method for producing optically active 3-aminopiperidine or salt thereof
WO2014178078A3 (en) Novel cloning, expression &amp; purification method for the preparation of ranibizumab
WO2010093182A3 (en) Microorganism for producing l-amino acids and method for producing l-amino acids using same
WO2018069418A3 (en) Production of citronellal and citronellol in recombinant hosts
WO2010102778A3 (en) Substituted 3-aminoisoxazolopyridines as kcnq2/3 modulators
WO2010030091A3 (en) Method for producing biological heme iron, and iron supplementing composition containing the heme iron produced by same
MX2015001542A (en) Method.
WO2009115252A3 (en) Substituted pyrazolamides and the use thereof
WO2012086988A3 (en) Artificial silk membrane having excellent flexibility and suturing ability and method of manufacturing the same
WO2010098583A2 (en) Novel method for preparing statin compounds or salts thereof, and intermediate compounds used in same
WO2010103548A3 (en) Improved method for producing lactic acid and derivative thereof
WO2009147179A3 (en) Process of producing male sterile monocotyledonous plants
UA96008C2 (en) Method for preparing high purity 3-carboxy-n,n,n-trimethyl-1-propanaminium hydroxide inner salt

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10801675

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10801675

Country of ref document: EP

Kind code of ref document: A2